US Markets
Home›US Markets›M&A & Deals›Pharma M&A chiefs warned against buying deals while fa…
Pharma M&A chiefs warned against buying deals while facing gaps
The WSJ says pharma executives are constantly searching for replacements for expiring blockbusters, but rushing acquisitions can drive costly errors.
Pharmaceutical executives are always looking for new drugs to replace expiring blockbusters, creating a steady backdrop for mergers and acquisitions, according to WSJ Markets.
The outlet cautions that pursuing deals while “hungry,” meaning when internal pipelines or product timelines are under pressure, can increase the risk of expensive mistakes.
← Newer storyDollar risks mount as softer data and Fed uncertainty loomOlder story →Commodity ship traffic at Strait of Hormuz drops further after attack
More like this
Sources
WSJ MarketsThe Key to Pharma M&A: Never Shopping Hungry